Bispecific J&J Drug Wins Speedy FDA Approval for Treating Head & Neck Cancer

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 06 Nov, 22:35 UTC

Accelerated FDA approval of Johnson & Johnson’s Rybrevant Faspro covers advanced cases of head and neck cancer. The bispecific antibody was initially approved for treating certain lung cancers. The post Bispecific J&J Drug Wins Speedy FDA Approval for Treating Head & Neck Cancer appeared first on…

science

Sources

• T2Bispecific J&J Drug Wins Speedy FDA Approval for Treating Head & Neck CancerFierce Biotech / Fierce Healthcare / MedCity / GEN06 Nov, 22:35